Tung Tran, MD
Family Medicine · Oklahoma City, OKNPI 1598027377
Payments from drug & device makers
Across 349 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$741
- AstraZeneca$711
- Novo Nordisk$538
- Boehringer Ingelheim$431
- AbbVie$346
- Merck$326
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,25899%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 55 | $741 |
| AstraZeneca | 35 | $711 |
| Novo Nordisk | 41 | $538 |
| Boehringer Ingelheim | 28 | $431 |
| AbbVie(2 entities) | 20 | $346 |
| Merck | 28 | $326 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $241 |
| Pfizer | 21 | $240 |
| GSK | 15 | $217 |
| Amgen | 11 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $181 |
| Astellas Pharma US Inc | 12 | $176 |
| Sanofi-aventis U.S. LLC | 9 | $159 |
| Genentech USA, Inc. | 6 | $108 |
| Johnson & Johnson | 8 | $101 |
| Abbott | 4 | $72 |
| Novartis | 4 | $64 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 3 | $49 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Amarin Pharma, Inc. | 3 | $39 |
| Gilead | 2 | $29 |
| Bayer | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Pacira Therapeutics, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$124
How this compares
$5,314 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 101 | $143,120 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $59,347 |
| TrulicityDulaglutide | 38 | $48,852 |
| EliquisApixaban | 38 | $40,235 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $39,824 |
| JanuviaSitagliptin Phosphate | 28 | $35,829 |
| JardianceEmpagliflozin | 23 | $28,902 |
| OzempicSemaglutide | 20 | $28,351 |
| LinzessLinaclotide | 23 | $25,846 |
| FarxigaDapagliflozin Propanediol | 14 | $21,296 |
| XareltoRivaroxaban | 23 | $19,988 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,012 |
| Varenicline Tartrate | 11 | $4,912 |
| Omeprazole | 219 | $4,378 |
| Atorvastatin Calcium | 358 | $3,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $741 | $191,972139 claims |
| GSKTrelegy Ellipta | $217 | $59,34758 claims |
| PfizerEliquis, Paxlovid | $240 | $41,66452 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $159 | $39,82432 claims |
| MerckJanuvia | $326 | $35,82928 claims |
| Boehringer IngelheimJardiance | $431 | $28,90223 claims |
| Novo NordiskOzempic | $538 | $28,35120 claims |
| AbbVieLinzess | $346 | $25,84623 claims |
| AstraZenecaFarxiga | $711 | $21,29614 claims |
| Johnson & JohnsonXarelto | $101 | $19,98823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.